Skip to content

Investigation on a New Power Knee Firmware Update on Gait and Daily Life Activities for Transfemoral Amputees

Investigation on a New Power Knee Firmware Update on Gait and Daily Life Activities, a Randomized Controlled Double-blinded Cross-over Investigation

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06620861
Enrollment
6
Registered
2024-10-01
Start date
2024-12-02
Completion date
2024-12-06
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Transfemoral Amputation

Keywords

Microprocessor knee, prosthesis, powered prosthesis

Brief summary

The goal of this interventional study is to investigate a new firmware in development for Power Knee on gait and daily life activities in unilateral transfemoral amputees. The main question it aims to answer is: What are the effects of a new firmware on sit-to-stand, level walking and stair ascent ? Researchers will compare both a new and the current marketed firmware to see if there is any changes in performance. Participants will be asked to perform some activities of daily living and some functional tests.

Interventions

DEVICEPower Knee Firmware Update

The firmware in development will be uploaded to the device.

DEVICEPower Knee Current Marketed Firmware

The current marketed firmware will be uploaded to the device.

Sponsors

Össur Iceland ehf
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 50 kg \< body weight \< 116 kg * lower limb loss, amputation or deficiency * cognitive ability to understand all instructions and questionnaires in the study * Unilateral transfemoral amputees that are regular Power Knee users for at least 4 weeks * age ≥ 18 years * Moderate to high active subjects * Willing and able to participate in the study and follow the protocol * Comfortable and stable socket fit * No socket issues/changes in the last 6 weeks

Exclusion criteria

* Users with pain * Bilateral amputees * Users using passive microprocessor controlled knees * Users with cognitive impairment * Users with co-morbidities in the contra lateral limb, which affect their functional mobility * Hip disarticulation amputees * Users with osseointegrated prosthesis * Pregnant users

Design outcomes

Primary

MeasureTime frameDescription
Sit to Stand Activityafter acclimatization at day 1 during the single study eventEach participant rated whether the new investigational firmware was worse, similar, or better compared to the current marketed firmware when performing sit to stand activity
Stand to Sit Activityafter acclimatization at day 1 during the single study eventEach participant rated whether the new investigational firmware was worse, similar, or better compared to the current marketed firmware when performing stand to sit activity
Level Ground Walkingafter acclimatization at day 1 during the single study eventEach participant rated whether the new investigational firmware was worse, similar, or better compared to the current marketed firmware when performing level ground walking.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPete Simpson

Össur Americas

Participant flow

Pre-assignment details

6 subjects with transfemoral amputation provided informed consent and were formally enrolled in the study, as reflected in the Protocol Section (6). However, one enrolled subject did not proceed to randomization due to low activity level and fatigue, and therefore did not start the intervention. As a result, only 5 participants were assigned to an Arm/Group and included in the Participant Flow module (5), and their data are presented in the Baseline Characteristics and analysis.

Baseline characteristics

Characteristic
Age, Continuous55.4 years
STANDARD_DEVIATION 11.7
Amputation level Transfemoral5 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 3
other
Total, other adverse events
0 / 20 / 3
serious
Total, serious adverse events
0 / 20 / 3

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026